Chronic Kidney Disease Drug Market, By Drug Class (ACE Inhibitors, B-Blockers, Calcium Channel Blockers, Diuretics, Erythropoiesis-Stimulating Agents (ESAs) and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Geography (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Trends, Analysis and Forecast till 2034

Chronic Kidney Disease Drug Market was valued at US$ 14.2 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 4.3% to reach US$ 20.8 billion by 2034.

Chronic kidney disease or chronic kidney failure is fatal condition, associated with gradual loss of kidney function, over the period of time. Chronic kidney condition will get worse, if the damaged kidney have not been diagnosed and treated. In the early stages of chronic kidney disease, patient may observe certain sign or symptoms. However, chronic kidney can progress to end-stage kidney failure, which is fatal and only be treated with dialysis (artificial filtering) or kidney transplant. 

Treatment for chronic kidney disease is focus on slowing the progression of kidney damage, depending on the underlying cause of kidney dysfunction. Various factors leading to increase the risk of chronic kidney disease includes high blood pressure, diabetes, obesity, and smoking, among others. Management of chronic kidney disease involves managing the co-morbidities such as blood pressure, treatment regimen to lower the cholesterol in diabetes medications and anemia treatment. Increasing prevalence of high blood pressure, obesity and diabetes leading to cause chronic kidney disease among the patients, is expected to drive the growth of chronic kidney disease drug market. 

The global chronic kidney disease drug market has been segmented on the basis of drug class, distribution channel and region.

On the basis of drug class, the chronic kidney disease drug market is segmented into ACE inhibitors, B-blockers, calcium channel blockers, diuretics, erythropoiesis-stimulating agents (ESAs), and others. Further, the distribution channel for chronic kidney disease drug market includes hospital pharmacies, retail pharmacies and online pharmacies. 

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the chronic kidney disease drug market. Factors responsible for the growth of market includes substantial rise in the awareness among the people regarding the risk of chronic kidney failure. Initiatives taken by key players in the market and government agencies in educating the people regarding possible risk factors associated with gradual loss of kidney function is expected to boost the market growth over the forecast period.

The key players operating in the global chronic kidney disease drug market includes Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline plc, and Keryx Biopharmaceuticals Inc.

• In May 2024, a popular diabetes medication has been found to prevent kidney failure and reduce deaths in people with type 2 diabetes and chronic kidney disease. Antidiabetic medication semaglutide, more widely known by brand names Ozempic and Wegovy, significantly reduces the risk of kidney failure, substantial loss of kidney function and death from kidney or cardiovascular causes, an international clinical trial led by UNSW Sydney researchers has shown. 
• In April 2024, hot climates worsen chronic kidney disease outcomes. Chronic kidney disease patients living in the hottest countries experienced an additional 8% drop in kidney function each year compared to those living in temperate climates, finds a new study from researchers at UCL and the London School of Hygiene & Tropical Medicine (LSHTM).
• In March 2024, Improving Global Outcomes (KDIGO) organization has released a new 2024 clinical practice guideline document on evaluating and managing nondialysis-dependent chronic kidney disease (CKD). Key highlights include guidance updates on the measurements of estimated glomerular filtration rate (eGFR) and albuminuria, use of CKD risk prediction equations, and personalized treatment recommendations for kidney and cardiovascular risk reductions tailored to individual patient needs and preferences. Managing blood pressure, diabetes, lipids, CKD-MBD, and anaemia has been addressed in detail in other KDIGO guidelines.